Lindbrook Capital’s Ascendis Pharma A/S ASND Stock Holding History

Lindbrook Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$44.3K	Sell	284 -6	-2%	-$857	﹤0.01%	1059
2024 Q4	$39.9K	Buy	290 +1	+0.3%	+$131	﹤0.01%	914
2024 Q3	$43.2K	Buy	289 +1	+0.3%	+$135	﹤0.01%	895
2024 Q2	$39.3K	Sell	288 -1	-0.3%	-$136	﹤0.01%	901
2024 Q1	$43.7K	Buy	289 +1	+0.3%	+$143	﹤0.01%	826
2023 Q4	$36.3K	Buy	288 +5	+2%	+$499	﹤0.01%	886
2023 Q3	$26.5K	Sell	283 -14	-5%	-$1.31K	﹤0.01%	928
2023 Q2	$26.5K	Sell	297 -157	-35%	-$13.7K	﹤0.01%	954
2023 Q1	$48.7K	Sell	454 -80	-15%	-$9.15K	0.01%	706
2022 Q4	$65.2K	Buy	534 +43	+9%	+$4.99K	0.01%	600
2022 Q3	$51K	Sell	491 -22	-4%	-$2.09K	0.01%	629
2022 Q2	$48K	Buy	513 +116	+29%	+$10.9K	0.01%	669
2022 Q1	$47K	Sell	397 -1	-0.3%	-$116	0.01%	704
2021 Q4	$54K	Sell	398 -127	-24%	-$18.9K	0.01%	686
2021 Q3	$84K	Sell	525 -12	-2%	-$1.64K	0.02%	303
2021 Q2	$71K	Buy	537 +97	+22%	+$12.9K	0.02%	366
2021 Q1	$57K	Buy	440 +28	+7%	+$4.25K	0.01%	399
2020 Q4	$69K	Buy	412 +3	+0.7%	+$496	0.02%	315
2020 Q3	$63K	Buy	409 +99	+32%	+$14.2K	0.02%	295
2020 Q2	$46K	Sell	310 -100	-24%	-$13.7K	0.01%	370
2020 Q1	$46K	Sell	410 -542	-57%	-$70.4K	0.02%	338
2019 Q4	$132K	Buy	952 +100	+12%	+$11.1K	0.05%	204
2019 Q3	$82K	Buy	852 +387	+83%	+$43.2K	0.03%	276
2019 Q2	$53K	Sell	465 -200	-30%	-$23.9K	0.02%	400
2019 Q1	$78K	Sell	665 -200	-23%	-$17.5K	0.03%	275
2018 Q4	$54K	Buy	+865	New	+$54.4K	0.03%	315

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's ASND Position: Q1 2025 in Review

Lindbrook Capital reduced its Ascendis Pharma A/S (ASND) stake by 2.1% in Q1 2025, selling an estimated $857 and leaving 284 shares worth $44.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

Lindbrook Capital first reported a position in ASND in Q4 2018 and has held it in 26 quarters since. The position peaked at $132K in Q4 2019. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

Lindbrook Capital held 284 shares of Ascendis Pharma A/S worth $44.3K as of Q1 2025.
Lindbrook Capital sold 6 Ascendis Pharma A/S shares in Q1 2025, an estimated $857.
Ascendis Pharma A/S made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1059 holding.
Lindbrook Capital first reported a position in Ascendis Pharma A/S in Q4 2018 and has held it in 26 quarters since.
Lindbrook Capital's Ascendis Pharma A/S position peaked at $132K in Q4 2019.
244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.